Holen Sie sich die Stockscreener-App
13.00
7.08%
-0.99
Schlusskurs vom Vortag:
$13.99
Offen:
$13.8
24-Stunden-Volumen:
276.10K
Relative Volume:
3.93
Marktkapitalisierung:
$538.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.04%
1M Leistung:
+0.00%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.92
$14.32
1-Wochen-Bereich:
$12.92
$15.38
52-Wochen-Spanne:
$12.92
$18.84
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Firmenname
Maplight Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie MPLT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
13.00 | 610.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.00 | 108.28B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.45 | 79.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.23 | 57.65B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
906.74 | 56.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.93 | 42.39B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-21 | Eingeleitet | Jefferies | Buy |
| 2025-11-21 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-21 | Eingeleitet | Stifel | Buy |
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
MapLight Therapeutics Closes Successful IPO and Private Placement - MSN
MapLight Therapeutics stock rating reiterated at Overweight by Morgan Stanley - Investing.com Canada
MapLight Therapeutics initiated with a Buy at Stifel - MSN
Jefferies & Co Initiates Coverage on MapLight Therapeutics With Buy Rating, $32 Price Target - MarketScreener
Morgan Stanley Initiates MapLight Therapeutics at Overweight With $34 Price Target - MarketScreener
MPLT Analyst Forecasts - Quiver Quantitative
MapLight Therapeutics stock initiated with Outperform rating by Leerink Partners - Investing.com Canada
Buy Recommendation for MapLight Therapeutics: Promising Pipeline and Market Potential - TipRanks
Promising Investment in MapLight Therapeutics: Buy Rating Backed by Strategic Positioning and Strong Financials - TipRanks
MapLight Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | MPLT | US56565P1030 - MarketScreener
MapLight Therapeutics stock initiated with Buy rating at Jefferies By Investing.com - Investing.com Canada
MapLight Therapeutics stock initiated with Buy rating by Stifel - Investing.com Canada
Morgan Stanley initiates MapLight Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
MapLight Therapeutics, Inc. (MPLT) Balance Sheet - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Latest Press Releases & Corporate News - Yahoo! Finance Canada
MapLight Therapeutics, Inc. share price - Capital.com
Timothy John Garnett Net Worth (2025) - GuruFocus
Erin Pennock Foff Net Worth (2025) - GuruFocus
Anatol Kreitzer Net Worth (2025) - GuruFocus
Vishwas Setia Net Worth (2025) - GuruFocus
Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More - AOL.com
MapLight Therapeutics, Inc. (MPLT) stock major holders - Yahoo Finance UK
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
Long term debt to total assets ratio of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Maplight Therapeutics (MPLT) 10K Form and SEC Filings 2025 - MarketBeat
Maplight Therapeutics (MPLT) Stock Chart and Price History 2025 - MarketBeat
Evommune nabs $150M in IPO amid federal shutdown - BioPharma Dive
Maplight Therapeutics (MPLT) Competitors and Alternatives 2025 - MarketBeat
MapLight Therapeutics, Inc. (MPLT) Stock Major Holders - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) stock historical prices and data - Yahoo Finance UK
Operating cash flow per share of MapLight Therapeutics, Inc. – BOATS:MPLT - TradingView
Long term debt to total assets ratio of MapLight Therapeutics, Inc. – BOATS:MPLT - TradingView
MapLight Therapeutics, Inc. Cash Flow – BOATS:MPLT - TradingView
MapLight Therapeutics, Inc. (MPLT) options chain - Yahoo Finance UK
Net current asset value per share of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Sergey Brin Nonprofit Gets $261 Million Lift in MapLight IPO - MSN
U.S. IPO Weekly Recap: Navan Slips, And Medline Joins The Pipeline To Close Out October - Seeking Alpha
Finance Watch: MapLight Brings US Biopharma IPO Tally To 11 In 2025 - Citeline News & Insights
Major Investment Alert: A S Novo’s Multi-Million Dollar Bet on MapLight Therapeutics! - TipRanks
Drug developer Evommune to go public next week, following MapLight's successful IPO - The Business Journals
MapLight Therapeutics completes $296 million IPO on nasdaq - Investing.com
Inflammation biotech Evommune prices IPO after MapLight's $250M debut - Fierce Biotech
Catalyst4, Inc. Makes a Major Move with a Massive Stock Purchase in MapLight Therapeutics! - TipRanks
MapLight Therapeutics, Inc. (MPLT) Latest Stock News & Headlines - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Stock Forum & Discussion - Yahoo! Finance Canada
MapLight Therapeutics, Inc. (MPLT) Interactive Stock Chart - Yahoo! Finance Canada
MapLight Therapeutics completes $296 million IPO on nasdaq By Investing.com - Investing.com Nigeria
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - Benzinga
Cash from investing activities of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Finanzdaten der Maplight Therapeutics Inc-Aktie (MPLT)
Es liegen keine Finanzdaten für Maplight Therapeutics Inc (MPLT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
4.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):